Paratek Pharmaceuticals (PRTK): Analyst Day Takeaways - Baird

November 18, 2016 6:48 AM EST
Get Alerts PRTK Hot Sheet
Price: $13.40 +1.13%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade PRTK Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst, Michael Ulz, reiterated his Outperform rating on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) after an analyst day focused on omadacycline’s promising profile and encouraging value proposition.

Data from the OASIS study were highlighted along with notable updates from a number of Phase 1 studies that provided proof-of-principal in UTI and increased the analyst's confidence in CABP.

The analyst continues to believe omadacycline is underappreciated with what is expected to be a transformational 2017 (Phase 3 data from oral-only ABSSSI 2Q17 and CABP 3Q17).

No change to the price target of $40.

For an analyst ratings summary and ratings history on Paratek Pharmaceuticals click here. For more ratings news on Paratek Pharmaceuticals click here.

Shares of Paratek Pharmaceuticals closed at $13.00 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Management Comments

Related Entities

Robert W Baird

Add Your Comment